

**Human Estrogen Receptor Beta  
(ER $\beta$ ; ESR2; NR3A2)  
Reporter Assay System**

**3x 32 Assays in 96-well Format**  
Product # IB00411-32

■ ■ ■


**Technical Manual**  
*(version 7.1bi)*

**[www.indigobiosciences.com](http://www.indigobiosciences.com)**

3006 Research Drive, Suite A1, State College, PA, 16801, USA

Customer Service:  
814-234-1919; FAX 814-272-0152  
[customerserv@indigobiosciences.com](mailto:customerserv@indigobiosciences.com)

Technical Service:  
814-234-1919  
[techserv@indigobiosciences.com](mailto:techserv@indigobiosciences.com)



## Human ER $\beta$ Reporter Assay System

### 3x 32 Assays in 96-well Format

#### I. Description

- The Assay System.....3
- The Assay Chemistry.....3
- Preparation of Test Compounds.....4
- Assay Scheme.....4
- Assay Performance.....5

#### II. Product Components & Storage Conditions .....7

#### III. Materials to be Supplied by the User.....7

#### IV. Assay Protocol

- A word about *Antagonist*-mode assay setup.....8
  - *DAY 1 Assay Protocol*.....8
  - *DAY 2 Assay Protocol*.....10

#### V. Related Products.....11

#### VI. Limited Use Disclosures.....11

#### APPENDIX 1: Example Scheme for Serial Dilution.....12

## I. Description

### ▪ The Assay System ▪

This nuclear receptor assay system utilizes proprietary non-human cells engineered to provide constitutive, high-level expression of the full-length **Human Estrogen Receptor 2 (NR3A2)**, a ligand-dependent transcription factor commonly referred to as **ERβ**.

INDIGO's Reporter Cells include the luciferase reporter gene functionally linked to a ERβ-responsive promoter. Thus, quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in ERβ activity. The principal application of this reporter assay system is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against human ERβ.

ERβ Reporter Cells are prepared using INDIGO's proprietary **CryoMite™** process. This cryo-preservation method yields exceptional cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for cumbersome intermediate treatment steps such as spin-and-rinse of cells, viability determinations, cell titer adjustments, or the pre-incubation of reporter cells prior to assay setup.

INDIGO Bioscience's Nuclear Receptor Reporter Assays are all-inclusive cell-based assay systems. In addition to ERβ Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user's test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate.

### ▪ The Assay Chemistry ▪

INDIGO's nuclear receptor reporter assay systems capitalize on the extremely low background, high-sensitivity, and broad linear dynamic range of bio-luminescence reporter gene technology.

Reporter Cells incorporate the cDNA encoding beetle luciferase, a 62 kD protein originating from the North American firefly (*Photinus pyralis*). Luciferase catalyzes the mono-oxidation of D-luciferin in a Mg<sup>+2</sup>-dependent reaction that consumes O<sub>2</sub> and ATP as co-substrates, and yields as products oxyluciferin, AMP, PP<sub>i</sub>, CO<sub>2</sub>, and photon emission. Luminescence intensity of the reaction is quantified using a luminometer and is reported in terms of Relative Light Units (RLU's).

INDIGO's Nuclear Receptor Reporter Assay Systems feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.

### ▪ Preparation of Test Compounds ▪

Small molecule test compounds are typically solvated in DMSO at high concentrations; ideally 1,000x-concentrated stocks relative to the highest desired treatment concentration in the assay. Using high-concentration stocks minimizes DMSO carry-over into the assay plates. Immediately prior to setting up an assay, the master stocks are serially diluted using one of two alternative strategies:

1.) As described in *Step 2*, and depicted in Appendix 1 for the reference agonist TO901317, **Compound Screening Medium (CSM)** may be used as the diluent to make serial dilutions of test compounds to achieve the desired final assay concentration series.

Alternatively, if test compound solubility is expected to be problematic,


2.) DMSO may be used to make serial dilutions, thereby generating 1,000x-concentrated stocks for each independent test concentration. Treatment media are then prepared using CSM to make final 1,000-fold dilutions of the prepared DMSO dilution series.

Regardless of the dilution method used, the final concentration of total DMSO carried over into assay wells should not exceed 0.4%. DMSO-induced cytotoxicity can be expected above 0.4%.


**NOTE:** CSM is formulated to help stabilize hydrophobic test compounds in the aqueous environment of the assay mixture. Nonetheless, high concentrations of extremely hydrophobic test compounds diluted in CSM may lack long-term stability and/or solubility, especially if further stored at low temperatures. Hence, it is recommended that test compound dilutions are prepared in CSM immediately prior to assay setup and are considered to be 'single-use' reagents.

### ▪ Assay Scheme ▪

**Figure 1.** Assay workflow. *In brief*, 100 µl/well of Reporter Cells are dispensed into wells of the assay plate, followed immediately by dispensing 100 µl/well of the prepared treatment media. Following 22-24 hours incubation, treatment media are discarded, and prepared Luciferase Detection Reagent (LDR) is added. The intensity of light emission (in units of 'Relative Light Units'; RLU) from each assay well is quantified using a plate-reading luminometer.



## ▪ Assay Performance ▪



**Figure 2. Activity dose-response of ERβ using various reference agonists.**


Dose-response analyses of ERβ were performed according to the protocol provided in this Technical Manual. Reporter Cells were treated with 17β-Estradiol (provided), DPN, Linquiritigenin, WAY 200070, and FERb 033 (all from Tocris). Average relative light units (RLU) and corresponding standard deviation (SD) values were determined for each treatment concentration (n = 4). Values of Fold-Activation (Signal / Background) and Z' were calculated as described by Zhang, *et al.* (1999)<sup>1</sup>. Non-linear regression and EC<sub>50</sub> analyses were performed using GraphPad Prism software.

**RESULTS:** EC<sub>50</sub> Z' values for 17β-estradiol confirm the robust performance of this ERβ Assay and demonstrate its suitability for use in HTS applications.<sup>1</sup>

<sup>1</sup> Zhang JH, Chung TD, Oldenburg KR. (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen.*:4(2), 67-73.

$$Z' = 1 - [3 * (SD^{\text{Reference}} + SD^{\text{Untreated}}) / (RLU^{\text{Reference}} - RLU^{\text{Untreated}})]$$

### Human ER $\beta$ Antagonist Assays



**Figure 3. Human ER $\beta$  antagonist-mode Assays**

ER $\beta$  antagonist assays were performed using Tamoxifen citrate, PHTPP and (R,R)-THC (all from Tocris). ER $\beta$  Assay setup and quantification of antagonist activities were performed following as described in this Technical Manual. The bulk suspension of reporter cells was supplemented with a 2x-EC<sub>75</sub> concentration of 17 $\beta$ -Estradiol and dispensed into the assay plate at 100  $\mu$ l/well. Cells were then further treated by adding 100  $\mu$ l/well of decreasing 2x-concentrations of antagonist. Assay plates were incubated for ~23 hrs, then processed to quantify ER $\beta$  activity for each treatment condition.

## II. Product Components & Storage Conditions

This Human ER $\beta$  assay kit contains materials to perform three distinct groups of assays in a 96-well plate format. Reagents are configured so that each group will comprise 32 assays. If desired, however, reagents may be combined to perform either 64 or 96 assays.

**Reporter cells are temperature sensitive! To ensure maximal viability the tube of cells must be maintained at -80°C until immediately prior to the rapid-thaw procedure described in Step 3 of this protocol.**

Assay kits are shipped on dry ice. Upon receipt of the kit transfer it to -80°C storage. If you wish to first inspect and inventory the individual kit components be sure to first transfer and submerge the tube of cells in dry ice.

The aliquot of Reporter Cells is provided as a single-use reagent. Once thawed, reporter cells can NOT be refrozen, nor can they be maintained in extended culture with any hope of retaining downstream assay performance. Therefore, extra volumes of these reagents should be discarded after assay setup.

The date of product expiration is printed on the Product Qualification Insert (PQI) enclosed with each kit.

| <u>Kit Components</u>                                                        | <u>Amount</u>  | <u>Storage Temp.</u> |
|------------------------------------------------------------------------------|----------------|----------------------|
| ▪ ER $\beta$ Reporter Cells                                                  | 3 x 0.60 mL    | <b>-80°C</b>         |
| ▪ Cell Recovery Medium (CRM)                                                 | 1 x 10.5 mL    | -20°C                |
| ▪ Compound Screening Medium (CSM)                                            | 1 x 35 mL      | -20°C                |
| ▪ 17 $\beta$ -Estradiol, 200 nM (in DMSO)<br>(E2, reference agonist for ERs) | 1 x 30 $\mu$ L | -20°C                |
| ▪ Detection Substrate                                                        | 3 x 2.0 mL     | <b>-80°C</b>         |
| ▪ Detection Buffer                                                           | 3 x 2.0 mL     | -20°C                |
| ▪ Plate frame                                                                | 1              | ambient              |
| ▪ Snap-in, 8-well strips<br>(white, sterile, cell-culture ready)             | 12             | ambient              |

## III. Materials to be Supplied by the User

The following materials must be provided by the user, and should be made ready prior to initiating the assay procedure:

### DAY 1

- dry ice bucket (*Step 3*)
- cell culture-rated laminar flow hood.
- 37°C, humidified 5% CO<sub>2</sub> incubator for mammalian cell culture.
- 37°C water bath.
- 70% alcohol wipes
- 8-channel electronic, repeat-dispensing pipettes & sterile tips
- disposable media basins, sterile.
- sterile multi-channel media basins (such as the Heathrow Scientific "Dual-Function Solution Basin"), *or* sterilized 96 deep-well blocks (*e.g.*, Axygen Scientific, #P-2ML-SQ-C-S), *or* appropriate similar vessel for generating dilution series of reference and test compound(s).
- *Optional*: antagonist reference compound (refer to Fig 3)
- *Optional*: clear 96-well assay plate, sterile, cell culture treated, for viewing cells on Day 2.

**DAY 2** plate-reading luminometer.

## IV. Assay Protocol

Review the entire Assay Protocol before starting. Completing the assay requires an overnight incubation. *Steps 1-8* are performed on **Day 1**, requiring less than 2 hours to complete. *Steps 9-14* are performed on **Day 2** and require less than 1 hour to complete.

### ▪ A word about Antagonist-mode assay setup ▪

Receptor inhibition assays expose the Reporter Cells to a constant, sub-maximal concentration (typically between EC<sub>50</sub> – EC<sub>80</sub>) of a known agonist AND the test compound(s) to be evaluated for antagonist activity. This ERβ Assay kit includes a 200 nM stock solution of **17β-Estradiol (E2)** a potent physiological agonist of ERβ that may be used to setup antagonist-mode assays. 12 pM 17-β-Estradiol approximates EC<sub>70-80</sub> in this assay. Hence, it is a suitable assay concentration of agonist to be used when screening test compounds for inhibitory activity.

Adding a 2x-EC<sub>80</sub> concentration of challenge agonist (E2) to the bulk suspension of Reporter Cells (*i.e.*, prior to dispensing into assay wells) is the most efficient and precise method of setting up antagonist assays, and it is the method presented in *Step 5b* of the following protocol. Note that, in *Step 6*, 100 µl of treatment media is combined with 100 µl of pre-dispensed [Reporter Cells + agonist]. Consequently, one must prepare the bulk suspension of Reporter Cells to contain a 2x-EC<sub>80</sub> concentration of E2 (approximately 24 pM). **APPENDIX 1** provides a dilution scheme that may be used as a guide when preparing cell suspension supplemented with a 2x-E2.

**DAY 1 Assay Protocol:** All steps must be performed using aseptic technique.

**1.) Remove Cell Recovery Medium (CRM) and Compound Screening Medium (CSM)** from freezer storage and thaw in a 37°C water bath.

**2.) Prepare dilutions of treatment compounds** (first see *Note 5.4*): Prepare Test Compound treatment media for *Agonist-* or *Antagonist-mode* screens.

Total DMSO carried over into assay reactions should never exceed 0.4%.

Note that, in *Step 6*, 100 µl of the prepared treatment media is added into assay wells that have been pre-dispensed with 100 µl of Reporter Cells. Hence, to achieve the desired *final* assay concentrations one must prepare treatment media with a 2x-concentration of the test and reference material(s). Use **CSM** to prepare the appropriate dilution series. Manage dilution volumes carefully. This assay kit provides 35 ml of CSM.

**Preparing the positive control:** This ERβ Assay kit includes a 200 nM stock solution of **17β-Estradiol**, a potent physiological agonist of ERβ that may be used as a reference compound. The following 7-point treatment series, with concentrations presented in 3-fold decrements, provides a complete dose-response: 200, 66.7, 22.2, 7.41, 2.47, 0.823, and 0.274 pM. Always include a 'no treatment' control. **APPENDIX 1** provides an example for generating such a dilution series.

**3.) Rapid Thaw of the Reporter Cells:** *First*, retrieve the tube of **CRM** from the 37°C water bath and sanitize the outside with a 70% ethanol swab.

*Second*, retrieve **Reporter Cells** from -80°C storage and immerse them in dry ice for transport to the laminar-flow hood: retrieve 1 tube for 32 assay wells, 2 tubes for 64 assay wells, and 3 tubes for 96 assay wells. When ready, transfer the tube(s) of frozen cells into a rack and, *without delay*, perform a rapid thaw of the frozen cells by transferring a 3.0 ml volume of 37°C CRM into each tube of frozen cells. Recap the tube(s) of cells and immediately place them in a 37°C water bath for 5 - 10 minutes. If only one tube of reporter cells is thawed (32 assays), the resulting volume of cell suspension will be 3.6 ml.

*Third*, during the 5 - 10 minutes incubation period, work in the cell culture hood to *carefully* mount four sterile 8-well strips into the blank assay plate frame. Strip-wells are fragile. Note that they have keyed ends (square and round), hence, they will fit into the plate frame in only one orientation.

4.) Retrieve the tube of Reporter Cell Suspension from the water bath. Sanitize the outside surface of the tube(s) with a 70% alcohol swab, then transfer it into the cell culture hood. If more than one tube cells were thawed, pool the individual tubes into a common reservoir.

5.) *a. Agonist-mode assays.* Gently invert the tube of Reporter Cells several times to disperse cell aggregates and gain a homogenous cell suspension. Dispense 100 µl of cell suspension into each well of the assay plate.

~ or ~

*b. Antagonist-mode assays.* Gently invert the tube of Reporter Cells several times to disperse any cell aggregates, and to gain a homogenous cell suspension. Supplement the bulk suspension of Reporter Cells with the desired 2x-concentration of reference agonist (refer to "A word about antagonist-mode assay setup", pg. 8). Dispense 100 µl of cell suspension into each well of the assay plate.

*NOTE 5.1:* If INDIGO's Live Cell Multiplex Assay is to be incorporated, a minimum of 3 'cell blank' wells (meaning cell-free but containing 'Compound Screening Media') must be included in the assay plate to allow quantification of plate-specific fluorescence background (refer to the LCMA Technical Manual).

*NOTE 5.2:* Take special care to prevent cells from settling during the dispensing period. Allowing cells to settle during the transfer process, and/or lack of precision in dispensing uniform volumes across the assay plate *will* cause well-to-well variation (= increased Standard Deviation) in the assay.

*NOTE 5.3:* Users sometimes wish to examine the reporter cells using a microscope. If so, the extra volume of cell suspension provided with each kit may be dispensed (100 µl/well) into a clear 96-well cell culture treated assay plate, followed by 100 µl/well of CSM. Incubated overnight in identical manner to those reporter cells contained in the white assay plate.

*NOTE 5.4:* For logistical reasons, some users find it more convenient to first plate the reporter cells and then prepare their test compound dilutions. That strategy works equally well. Once plated, cells may be placed in an incubator for up to 3 hours before proceeding to *Step 6*.

6.) Dispense 100 µl of 2x-concentration treatment media into appropriate assay wells.

7.) Transfer the assay plate into a cell culture incubator (37°C, humidified 5% CO<sub>2</sub>) for 22 - 24 hours.

NOTE: Ensure a high-humidity (≥ 70%) environment within the cell culture incubator. This is critical to prevent the onset of deleterious "edge-effects" in the assay plate.

8.) For greater convenience on *Day 2*, retrieve the appropriate number of vials of **Detection Substrate and Detection Buffer** from freezer storage and place them in a dark refrigerator (4°C) to thaw overnight.

**DAY 2 Assay Protocol:** Subsequent manipulations do *not* require special regard for aseptic technique and may be performed on a bench top.

9.) Approximately 30 minutes before intending to quantify ER $\beta$  activity, remove **Detection Substrate** and **Detection Buffer** from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature.

*NOTE:* Do NOT actively warm Detection Substrate above room temperature. If these solutions were not allowed to thaw overnight at 4°C, a room temperature water bath may be used to expedite thawing.

10.) Set the plate-reader to "luminescence" mode. Set the instrument to perform a single 5 second "plate shake" prior to reading the first assay well. Read time may be set to 0.5 second (500 mSec) per well, *or less*.

11.) *Immediately before proceeding to Step 12:* To read 32 assay wells, transfer the entire volume of 1 vial of Detection Buffer into 1 vial of Detection Substrate, thereby generating a 4 ml volume of **Luciferase Detection Reagent (LDR)**. Mix gently to avoid foaming.

12.) After 22-24 hours of incubation, remove media contents from each well.

*NOTE:* Because the assay plate is composed of a frame with snap-in strip-wells, the practice of physically ejecting media is NOT advised. Do *not* touch the well bottom or run the tip of the aspiration device around the bottom circumference of the assay well. Such practices will result in destruction of the reporter cells and greatly increased well-to-well variability. Complete removal of the media is efficiently performed by tilting the plate on edge and aspirating media using an 8-pin manifold (e.g., Wheaton Science Microtest Syringe Manifold, # 851381) affixed to a vacuum-trap apparatus.

13.) Add 100  $\mu$ l of **LDR** to each well of the assay plate. Allow the assay plate to rest at room temperature for at least 5 minutes. Do not shake the assay plate during this period.

14.) Quantify luminescence.

## V. Related Products

| <b>ER<math>\beta</math> Family of Assay Products</b>                                                       |                                                                                                                 |
|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| <b><i>Product No.</i></b>                                                                                  | <b><i>Product Descriptions</i></b>                                                                              |
| IB00411-32                                                                                                 | Human ER $\beta$ Reporter Assay System<br>3x 32 assays in 8-well strips (96-well plate format)                  |
| IB00411-48                                                                                                 | Human ER $\beta$ Reporter Assay System<br>2x 48 assays in 8-well strips (96-well plate format)                  |
| IB00411                                                                                                    | Human ER $\beta$ Reporter Assay System<br>1x 96-well format assay                                               |
| IB00412                                                                                                    | Human ER $\beta$ Reporter Assay System<br>1x 384-well format assays                                             |
| Bulk volumes of assay reagents may be custom manufactured to accommodate any scale of HTS. Please Inquire. |                                                                                                                 |
| <b>Panel of ER Assays</b>                                                                                  |                                                                                                                 |
| IB00421-48P                                                                                                | Human ER $\alpha$ and ER $\beta$ Reporter Assay PANEL<br>48 assays each in 8-well strips (96-well plate format) |

| <b>LIVE Cell Multiplex (LCM) Assay</b> |                                                                                                                               |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| LCM-01                                 | Reagent volumes sufficient to perform <b>96</b> Live Cell Assays in 1x96-well, or 2x48-well, or 3x32-well assay plate formats |
| LCM-05                                 | Reagent in <b>5x bulk volume</b> to perform <b>480</b> Live Cell Assays contained in 5 x 96-well assay plates                 |
| LCM-10                                 | Reagent in <b>10x bulk volume</b> to perform <b>960</b> Live Cell Assays contained in 10 x 96-well assay plates               |

| <b>INDIGlo Luciferase Detection Reagent</b> |                                                                                  |
|---------------------------------------------|----------------------------------------------------------------------------------|
| LDR-10, -25, -50, -500                      | INDIGlo Luciferase Detection Reagents in 10 mL, 25 mL, 50 mL, and 500 mL volumes |

Please refer to INDIGO Biosciences website for updated product offerings.

**[www.indigobiosciences.com](http://www.indigobiosciences.com)**

## VI. Limited Use Disclosures

Products offered by INDIGO Biosciences, Inc. are for RESEARCH PURPOSES ONLY – not for therapeutic, diagnostic, or contact use in humans or animals.

“CryoMite” is a Trademark <sup>TM</sup> of INDIGO Biosciences, Inc. (State College, PA, USA)

Product prices, availability, specifications, claims and technical protocols are subject to change without prior notice. The printed Technical Manual provided in the kit box will always be the most current version available.

Copyright © INDIGO Biosciences, Inc. (State College, PA, USA). All rights reserved.

## APPENDIX 1

Example scheme for the serial dilution of 17 $\beta$ -Estradiol reference agonist, and the setup of an ER $\beta$  dose-response assay.

